Lunai Bioworks Inc
Company Profile
Business description
Lunai Bioworks Inc is a biopharmaceutical company. Through its subsidiaries, it is mainly focused on developing allogeneic cell and gene therapies to promote stronger immune system responses, potentially for long-term or life-long cancer remission in some of the deadliest cancers. The group is engaged in the development of RENB-DC11 and RENB-DC20 (potential cell therapeutic vaccine candidates for different types of cancer); a proprietary AI platform that analyzes genetics to provide earlier and more accurate cancer diagnosis; and machine learning pipelines that harmonize and analyze complex, heterogeneous datasets to uncover clinically actionable insights. The group's reportable segments are: RENB, BioSymetrics, and RENC. Geographically, it operates in the United States and Netherlands.
Contact
2080 Century Park East
Suite 906
Los AngelesCA90067
USAT: +1 305 918-1980
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2026
Employees
29
Stocks News & Analysis
stocks
AI driving growth for ASX tech share
stocks
OpenAI is going public as the worst value among its peers
stocks
Wide moat healthcare leader remains undervalued
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,823.60 | 66.30 | 0.76% |
| CAC 40 | 8,199.29 | 18.95 | -0.23% |
| DAX 40 | 24,616.22 | 142.83 | -0.58% |
| Dow JONES (US) | 50,786.01 | 80.77 | -0.16% |
| FTSE 100 | 10,373.20 | 5.15 | 0.05% |
| HKSE | 24,620.26 | 36.80 | -0.15% |
| NASDAQ | 25,929.66 | 220.23 | 0.86% |
| Nikkei 225 | 65,230.84 | 1,206.24 | 1.88% |
| NZX 50 Index | 13,141.63 | 103.39 | 0.79% |
| S&P 500 | 7,405.73 | 21.99 | 0.30% |
| S&P/ASX 200 | 8,604.80 | 71.30 | 0.84% |
| SSE Composite Index | 3,979.68 | 20.34 | 0.51% |